Related Experiment Video
Updated: May 20, 2025
06:32
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
Published on: August 18, 2023
1.8K
A Practical Format to Organize Cancer Constellations Using Innate Immune System Biomarkers: Implications for Early
Martin Tobi1, Harvinder Talwar2, Noreen F Rossi3
1Department of Research and Development, Detroit VAMC, 4646 John R Street, Detroit, MI 48601, USA.
International Journal of Translational Medicine (Basel, Switzerland)
|March 25, 2025
Summary
New biomarkers, ferritin-fecal p87 (FERAD) and absolute neutrophil/lymphocyte ratio (aNLR), aid in cancer diagnosis and prognostication. These innate immune system biomarkers may also influence treatment outcomes and dietary interventions.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Cancer discovery traditionally focuses on specific cancer types for targeted therapies.
- Immune checkpoint therapeutics show broad success, encouraging exploration of other immune-modulating interventions.
Purpose of the Study:
- To identify novel innate immune system (InImS) biomarkers for cancer characterization.
- To explore the diagnostic, therapeutic, and prognostic potential of these InImS biomarkers.
Main Methods:
- Discovery of InImS biomarkers for characterizing cancer subtypes and outliers.
- Analysis of ferritin-fecal p87 (FERAD) and absolute neutrophil/lymphocyte ratio (aNLR).
Main Results:
- Identified FERAD and aNLR as InImS biomarkers.
- Demonstrated that these biomarkers reveal diagnostic and prognostication patterns.
- Linked InImS biomarkers to PD-L1 treatment outcomes.
Conclusions:
- FERAD and aNLR are valuable InImS biomarkers for cancer diagnosis and prognostication.
- These biomarkers offer insights into cancer subtypes and outliers.
- Potential for dietary manipulation of InImS biomarkers warrants further investigation.
